subscribeSubscribe
New Pharmacokinetic Modeling Data Presented by Teva at SIRS 2024

New Pharmacokinetic Modeling Data Presented by Teva at SIRS 2024
BUSINESSWIRE
06 Apr 2024
Share Share
Lyndra Announces Positive Data from Phase 3 Study with Oral Weekly Risperidone

Lyndra Announces Positive Data from Phase 3 Study with Oral Weekly Risperidone
BUSINESSWIRE
04 Jan 2024
Share Share
UZEDY Injectable Suspension Significantly Prolongs Time to Schizophrenia

UZEDY Injectable Suspension Significantly Prolongs Time to Schizophrenia
BUSINESSWIRE
01 Nov 2023
Share Share
Teva to Present Data for AUSTEDO Extended-Release Tablets, AUSTEDO Tablets

Teva to Present Data for AUSTEDO Extended-Release Tablets, AUSTEDO Tablets
BUSINESSWIRE
06 Sep 2023
Share Share
Teva to Present Data Demonstrating UZEDY Extended-Release Injectable Suspension Significantly Prolonged Time to Impending Relapse

Teva to Present Data Demonstrating UZEDY Extended-Release Injectable Suspension Significantly Prolonged Time to Impending Relapse
BUSINESSWIRE
20 May 2023
Share Share
FDA approves Teva, MedinCell`s long-acting schizophrenia therapy

FDA approves Teva, MedinCell`s long-acting schizophrenia therapy
Kevin Dunleavy FIERCE PHARMA
02 May 2023
Share Share
Teva and MedinCell Announce FDA Approval of UZEDY Injectable Suspension

Teva and MedinCell Announce FDA Approval of UZEDY Injectable Suspension
BUSINESSWIRE
28 Apr 2023
Share Share
US FDA approves Luye Pharma’s schizophrenia treatment Rykindo

US FDA approves Luye Pharma’s schizophrenia treatment Rykindo
PHARMACEUTICAL TECHNOLOGY
16 Jan 2023
Share Share
J&J Settles Most Risperdal Lawsuits, With $800 Million in Expenses

J&J Settles Most Risperdal Lawsuits, With $800 Million in Expenses
USNEWS
30 Oct 2021
Share Share
Teva to Present New Data from Growing Mental Health Portfolio at Psych

Teva to Present New Data from Growing Mental Health Portfolio at Psych
BUSINESSWIRE
21 Oct 2021
Share Share